Vitiligo and antitumor responses in melanoma reportedly depend on CD8+ T cells that recognize identical antigens, so-called melanocyte/melanoma-shared antigens (MSA), including Melan-A, tyrosinase, and premelanosome (PMEL), and can reduce melanoma mass and prevent tumor recurrence (2). Here, CD8A is linked to neoplasm.